U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H25ClN2OS
Molecular Weight 400.965
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ZUCLOPENTHIXOL

SMILES

OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC4=CC=C(Cl)C=C24)CC1

InChI

InChIKey=WFPIAZLQTJBIFN-DVZOWYKESA-N
InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-

HIDE SMILES / InChI
Molecular Formula C22H25ClN2OS
Molecular Weight 400.965
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987

Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. Zuclopenthixol, a thioxanthene derivative, has high affinity for both dopamine D1 receptors and dopamine D2 receptors. Zuclopenthixol also has high affinity for α1-adrenergic and 5-HT2 receptors. Zuclopenthixol (CLOPIXOL®) is avavilable in the form of tablets and solution for intramuscular injections.

CNS Activity

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Antagonist
2778
Antagonist
2778
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
CLOPIXOL

Approved Use

Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness.
Primary
Approved
8429
CLOPIXOL

Approved Use

Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness.
PubMed

PubMed

TitleDatePubMed
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.
1967
Prolonged oculogyric crisis on addition of nifedipine to neuroleptic medication regime.
1987 Jan
Zuclopenthixol and haloperidol/levomepromazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind, multi-centre study.
1989
Reversible lithium neurotoxicity at normal serum level may refer to intracranial pathology.
1989 May
Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.
1991 Dec
[acute dystonias in combined abuse of cocaine and neuroleptics].
1994 Nov 26
Effect of some psychotropic drugs and a barbiturate on mycoplasmas.
2000 Apr
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
2001 Jul
Fatal exertional heat stroke in a patient receiving zuclopenthixol, quetiapine and benztropine.
2007 Fall
Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate.
2014 Mar
Patents

Patents

US20080139573
7
WO/2008/069726A1
5

Sample Use Guides

In Vivo Use Guide
Clopixol tablets: The usual dose is 10 to 50 mg per day. Clopixol Acuphase injection: The usual dose is 50 to 150 mg (1 to 3 mL) every 2 to 3 days or as instructed by your doctor. Clopixol Depot injection: The usual dose is 200 to 400 mg (1 to 2 mL) every second to fourth week.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:02:43 GMT 2023
Edited
by admin
on Fri Dec 15 16:02:43 GMT 2023
Record UNII
47ISU063SG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZUCLOPENTHIXOL
INN   MART.   WHO-DD  
INN  
Official Name English
CLOPENTHIXOL CIS(Z)-FORM [MI]
Common Name English
zuclopenthixol [INN]
Common Name English
CLOPENTHIXOL CIS(Z)-FORM
MI  
Common Name English
Zuclopenthixol [WHO-DD]
Common Name English
ZUCLOPENTHIXOL [MART.]
Common Name English
CLOPIXOL
Brand Name English
Classification Tree Code System Code
WHO-ATC N05AF05
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
WHO-VATC QN05AF05
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
NCI_THESAURUS C29710
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
Code System Code Type Description
LACTMED
Zuclopenthixol
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
NCI_THESAURUS
C66713
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
MERCK INDEX
m3653
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY Merck Index
PUBCHEM
5311507
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
CHEBI
51364
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
WIKIPEDIA
ZUCLOPENTHIXOL
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
EVMPD
SUB00195MIG
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
ECHA (EC/EINECS)
258-758-5
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
DRUG CENTRAL
2877
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
RXCUI
114176
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL87385
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
DRUG BANK
DB01624
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
INN
5443
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
EPA CompTox
DTXSID3048233
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
FDA UNII
47ISU063SG
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
IUPHAR
7559
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
SMS_ID
100000078802
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
CAS
53772-83-1
Created by admin on Fri Dec 15 16:02:43 GMT 2023 , Edited by admin on Fri Dec 15 16:02:43 GMT 2023
PRIMARY
Related Record Type Details
Structure of ZUCLOPENTHIXOL HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of ZUCLOPENTHIXOL
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966